Q-omics provides the consensus-scored TRAJ39 profile across patient tissues and cancer cell-line models. TRAJ39 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TRAJ39 is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, TRAJ39 RNA expression shows 12,334 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, BLCA, and LSCC as cancer lineages where TRAJ39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ39 survival associations across molecular data types. TRAJ39 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ39 RNA expression–survival associations across cancer types. High TRAJ39 expression shows unfavorable associations in ACC, LIHC and LUSC, but favorable associations in UCEC, SKCM and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify UCEC as the clearest survival context for TRAJ39 RNA expression.
This table summarizes TRAJ39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ39 shows lower tumor expression in BLCA, READ, THCA and KIRP and higher tumor expression in LUAD and LIHC. The BLCA box plot shows higher TRAJ39 RNA expression in normal versus tumor tissue (log2 FC = −0.872, t-test p < 0.001).
This table shows molecular features associated with TRAJ39 in patient tissues and cancer cell lines. In patient samples, TRAJ39 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
